Eugenol Alleviates Cerebral Ischemia–Reperfusion Injury in Mice by Promoting the Phagocytosis of Microglia via Up-Regulating Tripartite Motif Protein 59
Mengtian Pan
School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China
Search for more papers by this authorXiang Li
School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China
Search for more papers by this authorXinjuan Tian
School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China
Search for more papers by this authorLele Zixin Yang
State College, The Pennsylvania State University, Eberly College of Science, Pennsylvania, USA
Search for more papers by this authorCorresponding Author
Weirong Fang
School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China
Correspondence:
Weirong Fang ([email protected])
Search for more papers by this authorMengtian Pan
School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China
Search for more papers by this authorXiang Li
School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China
Search for more papers by this authorXinjuan Tian
School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China
Search for more papers by this authorLele Zixin Yang
State College, The Pennsylvania State University, Eberly College of Science, Pennsylvania, USA
Search for more papers by this authorCorresponding Author
Weirong Fang
School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China
Correspondence:
Weirong Fang ([email protected])
Search for more papers by this authorSpecial Collection: Pharmacological Studies of Traditional Chinese Medicines.
Funding: This work was supported by the National Natural Science Foundation of China (grant number 82174051).
BCPT recognizes the potential of Natural Product studies in the identification of new therapies but wishes to emphasize that findings based on uncharacterized mixtures of compounds are preliminary in nature and serve primarily as hypothesis-generating to form the basis for more elaborate investigations.
ABSTRACT
Ischemic stroke (IS) is one of the most sinister diseases and the second leading cause of death in the world. Eugenol (EUG) is a natural and biologically active component that can be extracted from various plants. Studies have found that EUG can alleviate middle cerebral artery occlusion and reperfusion (MCAO/R) injury in mice, but the specific mechanism remains vague. Tripartite motif protein 59 (TRIM59) is a member of TRIM protein family, a group of E3 ubiquitin ligases. In this article, we conducted both in vivo and in vitro experiments to determine the effect of EUG on ischemia–reperfusion injury and to explore the underlying mechanisms by manipulating the expression of TRIM59. Results showed that EUG alleviates acute injury and promotes functional repair of mouse IS by enhancing the phagocytosis of microglia through up-regulating the TRIM59, activating the STAT3 pathway and promoting the expression of CD11b.
Conflicts of Interest
The authors declare no conflicts of interest.
Open Research
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Supporting Information
| Filename | Description |
|---|---|
| bcpt70058-sup-0001-Fig.S1.pngPNG image, 121.7 KB |
FIGURE S1. (A) The cell viability of cells after incubating eugenol (10, 30, 100, 300, 1000 μM) for 48 h. (B) The cell viability of BV2 cells after OGD/R for different time, n = 6. Data were shown as mean±SD. |
| bcpt70058-sup-0002-Suppl_material.docxWord 2007 document , 129 KB |
TABLE S1. Sequences of primers. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1M. Taleuzzaman, P. Jain, R. Verma, Z. Iqbal, and M. A. Mirza, “Eugenol as a Potential Drug Candidate: A Review,” Current Topics in Medicinal Chemistry 21, no. 20 (2021): 1804–1815.
- 2Z. Y. Xia, C. Luo, B. W. Liu, et al., “Shengui Sansheng Pulvis Maintains Blood-Brain Barrier Integrity by Vasoactive Intestinal Peptide After Ischemic Stroke,” Phytomedicine 67 (2020): 153158.
- 3M. F. Nisar, M. Khadim, M. Rafiq, J. Chen, Y. Yang, and C. C. Wan, “Pharmacological Properties and Health Benefits of Eugenol: A Comprehensive Review,” Oxidative Medicine and Cellular Longevity 2021 (2021): 2497354.
- 4J. Barot and B. Saxena, “Therapeutic Effects of Eugenol in a Rat Model of Traumatic Brain Injury: A Behavioral, Biochemical, and Histological Study,” Journal of Traditional and Complementary Medicine 11, no. 4 (2021): 318–327.
- 5C. F. Moreira Vasconcelos, N. M. da Cunha Ferreira, N. Hardy Lima Pontes, et al., “Eugenol and Its Association With Levodopa in 6-Hydroxydopamine-Induced Hemiparkinsonian Rats: Behavioural and Neurochemical Alterations,” Basic & Clinical Pharmacology & Toxicology 127, no. 4 (2020): 287–302.
- 6B. Pavan, A. Bianchi, G. Botti, et al., “Pharmacokinetic and Permeation Studies in Rat Brain of Natural Compounds Led to Investigate Eugenol as Direct Activator of Dopamine Release in PC12 Cells,” International Journal of Molecular Sciences 24, no. 2 (2023): 1800, https://doi.org/10.3390/ijms24021800.
- 7C. W. Tsao, A. W. Aday, Z. I. Almarzooq, et al., “Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association,” Circulation 145, no. 8 (2022): e153–e639.
- 8X. Dong, J. Gao, C. Y. Zhang, et al., “Neutrophil Membrane-Derived Nanovesicles Alleviate Inflammation To Protect Mouse Brain Injury From Ischemic Stroke,” ACS Nano 13, no. 2 (2019): 1272–1283.
- 9N. Ahmad, R. Ahmad, M. A. Alam, and F. J. Ahmad, “Quantification and Brain Targeting of Eugenol-Loaded Surface Modified Nanoparticles Through Intranasal Route in the Treatment of Cerebral Ischemia,” Drug Research (Stuttgart) 68, no. 10 (2018): 584–595.
- 10X. Sun, D. Wang, T. Zhang, et al., “Eugenol Attenuates Cerebral Ischemia-Reperfusion Injury by Enhancing Autophagy via AMPK-mTOR-P70S6K Pathway,” Frontiers in Pharmacology 11 (2020): 84.
- 11M. Pan, X. Li, G. Xu, X. Tian, Y. Li, and W. Fang, “Tripartite Motif Protein Family in Central Nervous System Diseases,” Cellular and Molecular Neurobiology 43, no. 6 (2023): 2567–2589.
- 12J. Jia, L. Yang, Y. Chen, L. Zheng, Y. Xu, and M. Zhang, “The Role of Microglial Phagocytosis in Ischemic Stroke,” Frontiers in Immunology 12 (2021): 790201, https://doi.org/10.3389/fimmu.2021.790201.
- 13A. Badimon, H. J. Strasburger, P. Ayata, et al., “Negative Feedback Control of Neuronal Activity by Microglia,” Nature 586, no. 7829 (2020): 417–423.
- 14X. Li, M. Pan, X. Tian, et al., “Myeloid Cell Trim59 Deficiency Worsens Experimental Ischemic Stroke and Alters Cerebral Proteomic Profile,” Journal of Inflammation Research 17 (2024): 4827–4843, https://doi.org/10.2147/JIR.S469651.
- 15K. Borst, A. A. Dumas, and M. Prinz, “Microglia: Immune and Non-immune Functions,” Immunity 54, no. 10 (2021): 2194–2208.
- 16J. C. Savage, M. Carrier, and M. E. Tremblay, “Morphology of Microglia Across Contexts of Health and Disease,” Methods in Molecular Biology 2034 (2019): 13–26.
- 17D. Nayak, T. L. Roth, and D. B. McGavern, “Microglia Development and Function,” Annual Review of Immunology 32 (2014): 367–402.
- 18O. Garaschuk and A. Verkhratsky, “Physiology of Microglia,” Methods in Molecular Biology 2034 (2019): 27–40.
- 19P. Tveden-Nyborg, B. Yang, U. Simonsen, and J. Lykkesfeldt, “BCPT Perspectives on Studies Involving Natural Products, Traditional Chinese Medicine and Systems Pharmacology,” Basic & Clinical Pharmacology & Toxicology 135, no. 6 (2024): 782–785.
- 20P. Tveden-Nyborg, T. K. Bergmann, N. Jessen, U. Simonsen, and J. Lykkesfeldt, “BCPT 2023 Policy for Experimental and Clinical Studies,” Basic & Clinical Pharmacology & Toxicology 133, no. 4 (2023): 391–396.
- 21L. Huang, Y. Chen, R. Liu, et al., “P-Glycoprotein Aggravates Blood Brain Barrier Dysfunction in Experimental Ischemic Stroke by Inhibiting Endothelial Autophagy,” Aging and Disease 13, no. 5 (2022): 1546–1561.
- 22S. Shahjouei, P. Y. Cai, S. Ansari, et al., “Middle Cerebral Artery Occlusion Model of Stroke in Rodents: A Step-by-Step Approach,” Journal of Vascular and Interventional Neurology 8, no. 5 (2016): 1–8.
- 23M. Franke, M. Bieber, P. Kraft, A. N. R. Weber, G. Stoll, and M. K. Schuhmann, “The NLRP3 Inflammasome Drives Inflammation in Ischemia/Reperfusion Injury After Transient Middle Cerebral Artery Occlusion in Mice,” Brain, Behavior, and Immunity 92 (2021): 223–233.
- 24S. K. Sarada, M. Titto, P. Himadri, et al., “Curcumin Prophylaxis Mitigates the Incidence of Hypobaric Hypoxia-Induced Altered Ion Channels Expression and Impaired Tight Junction Proteins Integrity in Rat Brain,” Journal of Neuroinflammation 12 (2015): 113.
- 25E. Z. Longa, P. R. Weinstein, S. Carlson, and R. Cummins, “Reversible Middle Cerebral Artery Occlusion Without Craniectomy in Rats,” Stroke 20, no. 1 (1989): 84–91.
- 26Y. Li, J. Chen, X. G. Chen, et al., “Human Marrow Stromal Cell Therapy for Stroke in rat: Neurotrophins and Functional Recovery,” Neurology 59, no. 4 (2002): 514–523.
- 27R. J. Carter, J. Morton, and S. B. Dunnett, “Motor Coordination and Balance in Rodents,” Current Protocols in Neuroscience 8 (2001): 8–12.
- 28T. Inaba, N. Miyamoto, K. Hira, et al., “Protective Role of Levetiracetam Against Cognitive Impairment and Brain White Matter Damage in Mouse Prolonged Cerebral Hypoperfusion,” Neuroscience 21, no. 414 (2019): 255–264.
10.1016/j.neuroscience.2019.07.015 Google Scholar
- 29G. C. Brown and J. J. Neher, “Microglial Phagocytosis of Live Neurons,” Nature Reviews. Neuroscience 15, no. 4 (2014): 209–216.
- 30X. Tong, P. Mu, Y. Zhang, J. Zhao, and X. Wang, “TRIM59, Amplified in Ovarian cancer, Promotes Tumorigenesis Through the MKP3/ERK Pathway,” Journal of Cellular Physiology 235, no. 11 (2020): 8236–8245.
- 31S. Yanakiev, “Effects of Cinnamon (Cinnamomum spp.) in Dentistry: A Review,” Molecules 25, no. 18 (2020): 4184, https://doi.org/10.3390/molecules25184184.
- 32H. Chen, L. Chen, Z. Shen, et al., “Synthesis of Mesoporous Silica Post-Loaded by Methyl Eugenol as An Environment-Friendly Slow-Release Bio Pesticide,” Scientific Reports 10, no. 1 (2020): 6108.
- 33Q. Hu, M. Zhou, and S. Wei, “Progress on the Antimicrobial Activity Research of Clove Oil and Eugenol in the Food Antisepsis Field,” Journal of Food Science 83, no. 6 (2018): 1476–1483.
- 34M. H. Won, J. C. Lee, Y. H. Kim, et al., “Postischemic Hypothermia Induced by Eugenol Protects Hippocampal Neurons From Global Ischemia in Gerbils,” Neuroscience Letters 254, no. 2 (1998): 101–104.
- 35Z. Cui, Z. Liu, J. Zeng, et al., “Eugenol Inhibits Non-Small Cell Lung Cancer by Repressing Expression of NF-kappaB-Regulated TRIM59,” Phytotherapy Research 33, no. 5 (2019): 1562–1569.
- 36D. B. Kim, B. Unenkhuu, G. J. Kim, S. W. Kim, and H. S. Kim, “Cynarin Attenuates LPS-Induced Endothelial Inflammation via Upregulation of the Negative Regulator MKP-3,” Animal Cells and Systemst (Seoul) 26, no. 3 (2022): 119–128.
- 37T. Qian, J. Hong, L. Wang, et al., “Regulation of CD11b by HIF-1alpha and the STAT3 Signaling Pathway Contributes to the Immunosuppressive Function of B Cells in Inflammatory Bowel Disease,” Molecular Immunology 111 (2019): 162–171.
- 38F. Yu, Y. Wang, A. R. Stetler, R. K. Leak, X. Hu, and J. Chen, “Phagocytic Microglia and Macrophages in Brain Injury and Repair,” CNS Neuroscience & Therapeutics 28, no. 9 (2022): 1279–1293.
- 39S. M. Ting, X. Zhao, G. Sun, L. Obertas, M. Ricote, and J. Aronowski, “Brain Cleanup as a Potential Target for Poststroke Recovery: The Role of RXR (Retinoic X Receptor) in Phagocytes,” Stroke 51, no. 3 (2020): 958–966.
- 40M. Kawabori, R. Kacimi, T. Kauppinen, et al., “Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) Deficiency Attenuates Phagocytic Activities of Microglia and Exacerbates Ischemic Damage in Experimental Stroke,” Journal of Neuroscience 35, no. 8 (2015): 3384–3396.
- 41J. J. Neher, J. V. Emmrich, M. Fricker, et al., “Phagocytosis Executes Delayed Neuronal Death After Focal Brain Ischemia,” Proceedings of the National Academy of Sciences of the United States of America 110, no. 43 (2013): E4098–E4107.
- 42S. Mensch, M. Baraban, R. Almeida, et al., “Synaptic Vesicle Release Regulates Myelin Sheath Number of Individual Oligodendrocytes In Vivo,” Nature Neuroscience 18, no. 5 (2015): 628–630.
- 43H. Baba, “Introduction to Myelin Research,” Yakugaku Zasshi 142, no. 8 (2022): 837–853.
- 44A. N. Hughes and B. Appel, “Microglia Phagocytose Myelin Sheaths to Modify Developmental Myelination,” Nature Neuroscience 23, no. 9 (2020): 1055–1066.
- 45R. C. Armstrong, A. J. Mierzwa, C. M. Marion, and G. M. Sullivan, “White Matter Involvement After TBI: Clues to Axon and Myelin Repair Capacity,” Experimental Neurology 275, no. Pt 3 (2016): 328–333.
- 46Y. Zhao, X. Zhang, X. Chen, and Y. Wei, “Neuronal Injuries in Cerebral Infarction and Ischemic Stroke: From Mechanisms to Treatment (Review),” International Journal of Molecular Medicine 49, no. 2 (2022): 15, https://doi.org/10.3892/ijmm.2021.5070.
- 47M. Olah, S. Amor, N. Brouwer, et al., “Identification of a Microglia Phenotype Supportive of Remyelination,” Glia 60, no. 2 (2012): 306–321.
- 48M. S. Natrajan, A. G. de la Fuente, A. H. Crawford, et al., “Retinoid X Receptor Activation Reverses Age-Related Deficiencies in Myelin Debris Phagocytosis and Remyelination,” Brain 138, no. Pt 12 (2015): 3581–3597, https://doi.org/10.1093/brain/awv289.
- 49S. A. Goldman and J. Osorio, “So Many Progenitors, so Little Myelin,” Nature Neuroscience 17, no. 4 (2014): 483–485.
- 50Y. Liu, C. Wu, Z. Hou, et al., “Pseudoginsenoside-F11 Accelerates Microglial Phagocytosis of Myelin Debris and Attenuates Cerebral Ischemic Injury Through Complement Receptor 3,” Neuroscience 426 (2020): 33–49.
- 51D. Su, Z. Jiao, S. Li, et al., “Spatiotemporal Single-Cell Transcriptomic Profiling Reveals Inflammatory Cell States in a Mouse Model of Diffuse Alveolar Damage,” Exploration (Beijing) 3, no. 3 (2023): 20220171.
- 52Y. Qian, Z. Yan, T. Ye, V. Shahin, J. Jiang, and C. Fan, “Decoding the Regulatory Role of ATP Synthase Inhibitory Factor 1 (ATPIF1) in Wallerian Degeneration and Peripheral Nerve Regeneration,” Exploration (Beijing) 4, no. 6 (2024): 20230098.
- 53Y. Li, T. Jin, N. Liu, et al., “A Short Peptide Exerts Neuroprotective Effects on Cerebral Ischemia-Reperfusion Injury by Reducing Inflammation via the miR-6328/IKKbeta/NF-kappaB Axis,” Journal of Neuroinflammation 20, no. 1 (2023): 53.
